Oncology is rapidly evolving from broad-spectrum treatments to highly individualized care. Predictive biomarkers are the molecular and cellular indicators of how a patient’s cancer will respond to therapy are central to this shift. Leveraging genomic profiling, proteomics, immunology and liquid-biopsy technologies, clinicians can now choose treatments tailored to tumor biology rather than just tumor type. This white paper explores the current landscape, clinical applications, challenges, and future direction of predictive biomarkers in cancer therapy, supported by current literature.

Introduction

Cancer remains one of the leading causes of morbidity and mortality worldwide. The heterogeneity of tumors in terms of genetics, epigenetics, microenvironment, and immune landscape makes “one-size-fits-all” treatments often insufficient. Predictive biomarkers enable more precise stratification of patients, offering optimized therapeutic benefit while minimizing unnecessary toxicity or cost. This approach underpins the transformation to precision oncology and is gaining strength with modern molecular diagnostics and bioinformatics.

Types of Predictive Biomarkers

Predictive biomarkers are defined as biological indicators that inform the likelihood of response to a specific therapeutic intervention. This distinguishes them from prognostic biomarkers, which provide information on disease outcome independent of treatment. Notably, several biomarkers discussed in this review—such as microsatellite instability (MSI) and tumor-infiltrating lymphocytes (TILs)—may exhibit both predictive and prognostic value. Where applicable, these dual roles are acknowledged to ensure conceptual clarity.

Genetic / Genomic Biomarkers

Genomic alterations, such as driver mutations, gene fusions, amplifications or deletions remain the bedrock of targeted therapy.

For example:

• Mutations in EGFR, ALK rearrangements, BRAF V600E and others in lung cancer.
• In colorectal cancer or gastrointestinal malignancies: KRAS, NRAS, BRAF, PIK3CA mutations and MSI status influence response to therapies.
These genomic biomarkers are identified via next-generation sequencing (NGS), PCR-based tests or specialized assays providing actionable data.
Protein-Level and Immunohistochemical Biomarkers
Beyond DNA, protein expression or receptor status is often more directly tied to therapy response.

Examples:

• HER2 overexpression in breast cancer guiding HER2-targeted agents.
• Hormone receptors (ER/PR) for endocrine therapy decisions in breast cancer.
• Immune checkpoint proteins, especially PD-L1 which assessed by immunohistochemistry to guide immunotherapy.
Immunological and Microenvironmental Biomarkers
Immuno-oncology depends heavily on biomarkers that reflect tumor–immune system interactions.

Common and emerging markers include:

• PD-L1 expression, used to predict response to immune checkpoint inhibitors. However, its utility is limited by inter-assay variability, heterogeneous expression within tumors, and imperfect correlation with clinical response.
• Tumor Mutational Burden (TMB) — high TMB often correlates with better immunotherapy responses because of increased neoantigen load. The absence of standardized cutoffs and differences between tissue-based and blood-based assays constrain its universal application.
• Microsatellite Instability (MSI) / Mismatch Repair Deficiency (dMMR): MSI-H/dMMR is a validated biomarker for responsiveness to checkpoint blockade across tumor types.
• Tumor-infiltrating lymphocytes (TILs) and immune cell signatures also have predictive potential. But require further prospective validation before routine clinical implementation

Liquid Biopsy & Circulating Biomarkers

Non-invasive modalities detect circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), or exosomal components, offering dynamic monitoring of tumor evolution or resistance. Comprehensive frameworks now propose combining liquid biopsy with molecular and phenotypic data for precision medicine.

Despite their clinical promise, liquid biopsy approaches face methodological limitations, including reduced sensitivity in low–tumor-burden settings and variability introduced by pre-analytical and analytical factors. Concordance between tissue-based and circulating biomarkers is not absolute, underscoring the need for standardized protocols and cautious interpretation when liquid biopsy is used as a surrogate for tissue profiling.

Clinical Applications of Predictive Biomarkers

Targeted Therapy SelectionBy identifying actionable genomic aberrations, biomarkers direct the use of kinase inhibitors, receptor-targeted agents, and other precision therapies. For example, EGFR mutations or ALK fusions in non-small cell lung cancer (NSCLC) facilitate the use of specific tyrosine-kinase inhibitors.

In colorectal and gastrointestinal cancers, RAS/BRAF status and MSI inform therapeutic decisions and eligibility for targeted agents or immunotherapy.

Immunotherapy Guidance

Immune checkpoint inhibitors (ICIs) benefit only a subset of patients. Predictive biomarkers such as PD-L1, TMB, MSI-H, and immune infiltrate help select those likely to respond — improving efficiency and reducing unnecessary exposure to immunotherapy-related toxicities.

Monitoring Response & Resistance (Adaptive Oncology)

Liquid biopsy enabling ctDNA/CTC monitoring allows early detection of emerging resistance, minimal residual disease, or relapse — enabling adaptive changes in therapy. Combined biomarker frameworks that integrate molecular, imaging, and immunologic data promise more precise, dynamic management.
Pan-Tumor / Tumor-Agnostic Treatment Decisions
Some biomarkers (e.g., MSI-H, high TMB, NTRK fusions, BRAF V600E) have led to “tissue-agnostic” approvals, where therapy is guided by biomarker status rather than tumor origin — broadening treatment across multiple cancer types.

Challenges and Limitations

Despite progress, several issues hamper universal implementation:
• Tumor heterogeneity and dynamic evolution can render a single biopsy insufficient. Biomarker status may change over time or differ between primary and metastatic lesions.
• Assay Variability and lack of standardization — Differences among testing platforms, including antibodies, sequencing panels, and cutoff definitions, can lead to inconsistent biomarker classification, particularly for PD-L1 expression and tumor mutational burden (TMB).
• Access and cost constraints, especially in low- and middle-income regions — many advanced biomarker tests and companion diagnostics are expensive and require specialized infrastructure.
• Insufficient predictive power for some biomarkers — e.g., PD-L1 negative patients may still respond to immunotherapy; high TMB does not guarantee response in all cancer types.
• Regulatory and ethical challenges — especially for broad genomic testing, data privacy, and interpretational complexity when multiple biomarkers are considered.
Future Directions
The future of predictive biomarker development in oncology is increasingly oriented toward integrative and dynamic approaches
• Multi-omics integration — combining genomics, transcriptomics, proteomics, epigenetics, and immune profiling for a comprehensive tumor fingerprint.
• Machine learning and AI-driven biomarker discovery — predicting response from computational models using molecular data, pathology images, or combined datasets.
• Real-time monitoring and adaptive treatment algorithms using liquid biopsy to detect emerging resistance and guide therapy adjustments.
• Expansion of tumor-agnostic approvals — therapies guided by biomarker status (e.g., MSI-H, TMB-H, NTRK fusions) rather than tumor site, widening eligible patient populations.
• Improved global access — development of cost-effective, scalable biomarker testing platforms and policy/regulatory frameworks to ensure equitable access across geographies.

IAIO Conclusion

Predictive biomarkers have emerged as a transformative pillar of contemporary oncology, enabling a paradigm shift from empiric, population-based treatment strategies to molecularly informed, patient-specific therapeutic interventions. By delineating actionable genomic, proteomic, and immunologic signatures, these biomarkers facilitate precise therapy selection, optimize pharmacodynamic response, and mitigate treatment-related toxicity. Sustained advancement in multi-omics technologies, bioinformatics pipelines, and regulatory standardization will be essential to fully integrate biomarker-guided approaches into routine clinical practice. As precision medicine evolves and tumor biology becomes increasingly well-characterized, predictive biomarkers will play a decisive role in improving progression-free survival, overall survival, and overall quality of life across diverse cancer populations.